Treatment Clinical Trials for Ewing Sarcoma

Clinical trials are research studies that involve people. The clinical trials on this list are for Ewing sarcoma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-34 of 34

  • A Study of EGFR806 CAR T-Cell Immunotherapy for Treating Children and Young Adults with Recurrent / Refractory Solid Tumors

    This phase I trial studies side effects and best dose of EGFR806-specific and EGFR806xCD19 CAR T cells and how well they work in treating patients with solid tumors that have come back (recurrent) or do not respond to treatment (refractory). T cells are a type of immune cell that can recognize proteins on the surface of other cells and then target and kill cells that have that protein. Some solid tumor cells have an EGFR protein on their surface, and T cells can be modified with a receptor, called a chimeric antigen receptor (CAR), to help recognize this protein and kill these tumor cells; this is the treatment in Arm A of this study. In Arm B of this study, researchers will modify T cells to recognize EGFR as well as a protein called CD19; CD19 is present on the surface of a group of normal white blood cells called B cells. Researchers hypothesize that modifying T cells to be directed against CD19 in addition to EGFR may act as an additional signal to help the T cells directed against EGFR to grow better and last longer.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

    This study is being done because new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1) is being studied. This study will be the first administration of a radioactive drug called 177Lu-3BP-227 to patients under controlled conditions of a clinical study. The purpose of this study is to evaluate how safe this investigational drug is as well to verify how well it is tolerated by patients after several intravenous administrations. In addition, we will evaluate the effect of the study drug on tumoral lesions and how it distributes throughout the body and at which rate it is removed from the body. Since 177Lu-3BP-227 is a radio-labelled drug, it will also be measured how the emitted radiation is distributed throughout the body (dosimetry). The study consists of a phase I with a dose escalation part (and potential expansion cohorts) and a phase II either in selected or over multiple indications in a basket approach. For the dose escalation part, it is anticipated that approximately 30 subjects will be included, in up to six escalation steps. In case of the implementation of phase I expansion cohorts, up to 45 additional subjects will be enrolled. For the phase II, approximately 125 subjects (55 Pancreatic ductal adenocarcinoma and 70 Colorectal cancer subjects) are planned to be enrolled for Basket trial or Optimal Simon's Two Stage design. If additional cohorts of subjects with Gastric cancer (GC) or Squamous-cell carcinoma of head and neck (SCCHN) in the phase II are to be studied, approximately 100 additional subjects will be enrolled.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

    The Phase 1 part of the study is conducted to determine the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D) of eribulin mesilate in combination with irinotecan hydrochloride in pediatric participants with relapsed / refractory solid tumors (excluding central nervous system [CNS] tumors). The Phase 2 part of the study is conducted to assess the objective response rate (ORR) and duration of response (DOR) of eribulin mesilate in combination with irinotecan hydrochloride in pediatric participants with relapsed / refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and ewing sarcoma (EWS).
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Akt / ERK Inhibitor ONC201 in Treating Patients with Neuroendocrine Tumors That Are Locally Advanced, Metastatic, Recurrent, Refractory, or Cannot Be Removed by Surgery

    This phase II trial studies how well akt / ERK inhibitor ONC201 works in treating patients with neuroendocrine tumors that have spread to nearby tissues or lymph nodes (locally advanced) or other places in the body (metastatic), have come back (recurrent), do not respond to treatment (refractory), or cannot be removed by surgery (unresctable). Akt / ERK inhibitor ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed / Refractory Hematologic Malignancies or High Risk Solid Tumors

    This phase I trial studies the side effects of zoledronic acid given after genetically modified donor stem cell transplant in treating younger patients with hematologic malignancies or high risk tumors that have returned after a period of improvement (relapsed) or do not respond to treatment (refractory). Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When healthy stem cells from a donor that have been genetically modified are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving mycophenolate mofetil and tacrolimus after the transplant may stop this from happening. Giving zoledronic acid after the transplant may help strengthen the immune system and make the immune cells work better.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Selinexor and Ixazomib for the Treatment of Locally Advanced Unresectable or Metastatic Sarcoma

    This phase I trial studies the side effects and best dose of selinexor when given together with ixazomib in treating patients with sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection (locally advanced unresectable) or has spread to other places in the body (metastatic). Selinexor blocks the activity of a protein which transports certain molecules between different parts of a cell. Many cancers disrupt the normal location of proteins and other molecules to allow the cancer to keep growing. Ixazomib is proteasome inhibitor. Proteasomes are responsible for breaking down certain proteins within the cell. Ixazomib allows some proteins and molecules to remain active for a longer time. Selinexor may work better in treating sarcoma when combined with ixazomib.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

    Background: - Some people with cancer have solid tumors. Others have refractory leukemia. This doesn t go away after treatment. Researchers want to see if a drug called PLX3397 can shrink tumors or stop them from growing. Objectives: - To find the highest safe dose and side effects of PLX3397. To see if it helps treat certain types of cancer. Eligibility: - People ages 3 22 with a solid tumor or leukemia that has returned or not responded to cancer therapies. - For Phase II, people ages 3 31 with a Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibroma (PN) that cannot be removed with surgery. Design: - Participants will be screened with: - Medical history - Physical exam - Blood and urine tests - Heart tests - Scans or other tests of the tumor - Participants will take PLX3397 as a capsule once daily for a 28-day cycle. They can do this for up to 2 years. - During the study, participants will have many tests and procedures. They include repeats of the screening tests. Participants will keep a diary of symptoms. - Participants with solid tumors will have scans or x-rays. - Participants with NF1 PN will have MRI scans. - Participants with leukemia will have blood tests. They may have a bone marrow sample taken. - Some participants may have a biopsy. - When finished taking PLX3397, participants will have follow-up visits. They will repeat the screening tests and note side effects. - Phase II will follow the same procedures as Phase I above, but participants will also fill out questionnaires about their pain and quality of life.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study

    This phase II trial studies how well sirolimus together with repetitive, low doses of chemotherapy (metronomic chemotherapy) works in treating children with high-risk solid tumors. Sirolimus is used to decrease the body's immune response. Chemotherapy drugs, such as etoposide and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sirolimus together with chemotherapy may help stop tumor growth by preventing blood from getting to the tumor and ultimately prevent the tumor from coming back.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Tazemetostat in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

    This phase II Pediatric MATCH trial studies how well tazemetostat works in treating patients with brain tumors, solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have come back (relapsed) or do not respond to treatment (refractory) and have EZH2, SMARCB1, or SMARCA4 gene mutations. Tazemetostat may stop the growth of tumor cells by blocking EZH2 and its relation to some of the pathways needed for cell proliferation.
    Location: 117 locations